Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.

Biotechnology

Monopteros

Monopteros' headquarters in Boston, MA, United States

Arthur DeCillis

Jon Lawson

Vijayapal Reddy

Sami Karaborni

Debasish Roychowdhury

Keith Flaherty

Shyam Masrani

John Baldoni

Ulrich von Andrian

Thorsten Mempel

Daniel Krappmann

Arlene Sharpe

Francesco De Rubertis

The Scientific Research and Development team at Monopteros Therapeutics is dedicated to advancing innovative therapeutic approaches, focusing on the development and optimization of the MPT-0118 inhibitor. This interdisciplinary team collaborates on drug development, conducts non-clinical safety assessments, and provides scientific guidance to ensure that the clinical trials effectively reprogram regulatory T cells for targeted cancer treatments. Through their expertise in chemistry and research, they aim to propel the company’s first-in-class therapies from conception to clinical application.

Scientific Research and Development

The Leadership Team at Monopteros Therapeutics is responsible for guiding the strategic direction and operational execution of the company. Comprised of seasoned executives and influential figures in the biotechnology field, the team collaborates to oversee clinical development, drive innovation, and ensure alignment with the company’s mission of advancing novel therapies for solid tumors. Their combined expertise in medical research, business strategy, and scientific advisory fosters a dynamic environment for the successful advancement of MPT-0118 through clinical trials.

Leadership Team

Monopteros

Org chart

Board & advisors

Teams

Scientific Research and Development

Leadership Team

Offices

Monopteros

Org chart

Board & advisors

Teams

Scientific Research and Development

Leadership Team

Offices

Related companies